Nitroglycerin
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | NITROLINGUAL | — | 1997-01-10 | fda.gov ↗ |
| Approved | US (FDA) | NITROGLYCERIN | — | 1981-05-28 | fda.gov ↗ |
Trials 94 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05239013 | May 2022 → Mar 2023 | arterial disorder | Thomas Jefferson University | Unknown | No outcome recorded |
| Phase 0 | NCT06172998 | Apr 2022 → Apr 2024 | obstructive sleep apnea syndrome | Xu J | Unknown | No outcome recorded |
| Phase 0 | NCT04155476 | Dec 2019 → Mar 2020 | peripheral arterial disease | Deborah Heart and Lung Center | Unknown | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT07004764 | Nov 2026 → Sep 2027 expected | — | Johns Hopkins University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07431294 | Oct 2026 → May 2027 expected | coronary artery disorder | Bayer | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04008732 | Nov 2017 → Apr 2018 | erectile dysfunction | Futura Medical Developments Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02617550 | Nov 2015 → May 2016 | coronary artery disorder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02425566 | Apr 2015 → Jul 2026 overdue | hypertensive disorder | Vanderbilt University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01407107 | Jan 2011 → Oct 2015 | rectal cancer | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00686231 | May → Dec 2008 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01616485 | Mar → May 2004 | erectile dysfunction | VIVUS LLC | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05442931 | May → Oct 2022 | — | Minia University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04685031 | Feb → Apr 2021 | phlebitis | Komar University of Science and Technology | Unknown | No outcome recorded |
| Phase 1/2 | NCT02577718 | Nov 2015 → Jun 2016 | nosocomial infection, prosthesis-related infectious disease | Novel Anti-Infective Technologies, LLC | Completed | No outcome recorded |
| Phase 221 trials | ||||||
| Phase 2 | NCT05635851 | Dec 2026 → Feb 2028 expected | autonomic dysreflexia, spinal cord injury | Simon Fraser University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07682454 | Aug 2026 → Feb 2029 expected | hepatocellular carcinoma | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06289946 | Mar 2024 → Mar 2025 | coronary artery disorder | Thomas Jefferson University | Unknown | No outcome recorded |
| Phase 2 | NCT03259165 | Dec 2017 → Dec 2021 | heart failure, pulmonary edema | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT03357731 | Nov 2017 → May 2019 | left ventricular failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02714205 | Apr 2017 → Mar 2022 | — | Alison Huang, MD | Completed | No outcome recorded |
| Phase 2 | NCT02688270 | Jun → Dec 2016 | Raynaud disease | Covis Pharma S.à.r.l. | Completed | No outcome recorded |
| Phase 2 | NCT02801305 | Jun 2016 → Jan 2017 | chronic ulcer of skin | Mohammad Ali Nazarinia | Completed | No outcome recorded |
| Phase 2 | NCT03235921 | Mar 2016 → Aug 2017 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT02495467 | May 2015 → Jul 2016 | erectile dysfunction | Futura Medical Developments Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01811693 | Apr → Sep 2013 | intracerebral hemorrhage, ischemic stroke | University of California, Los Angeles | Terminated | No outcome recorded |
| Phase 2 | NCT01210378 | Dec 2011 → Sep 2016 | non-small cell lung carcinoma | Maastricht Radiation Oncology | Terminated | No outcome recorded |
| Phase 2 | NCT01171170 | Jan 2011 → Jun 2014 | non-small cell lung carcinoma | Dutch Society of Physicians for Pulmonology and Tuberculosis | Completed | No outcome recorded |
| Phase 2 | NCT02327793 | Jun 2009 → Jul 2015 | ischemic stroke | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT00616031 | Jan 2008 → Dec 2011 | lung cancer | Kyoto University | Unknown | No outcome recorded |
| Phase 2 | NCT00641953 | Aug 2007 → Mar 2008 | diabetic neuropathy | Procris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00480753 | May → Aug 2007 | Raynaud disease | MediQuest Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00447928 | Apr → Nov 2007 | tendinitis | Cure Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT00886405 | Jul 2006 → Apr 2009 | non-small cell lung carcinoma | National Institute of Cancerology | Unknown | No outcome recorded |
| Phase 2 | NCT00090558 | Aug 2004 → Sep 2005 | coronary artery disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00001716 | Jul 1998 → Jul 2003 | intermediate coronary syndrome, sickle cell disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06785337 | Feb → Oct 2025 overdue | chronic obstructive pulmonary disease | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01155167 | Jul 2010 → Aug 2011 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2/3 | NCT00253331 | Nov 2004 → Sep 2005 | Raynaud disease | MediQuest Therapeutics | Completed | No outcome recorded |
| Phase 2/3 | NCT01279551 | Jan 2004 → Sep 2010 | — | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT04766151 | Jan → Dec 2021 | coronary vasospasm | 424 General Military Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04321967 | Aug 2019 → Nov 2022 | gynecomastia disorder | Icahn School of Medicine at Mount Sinai | Withdrawn | No outcome recorded |
| Phase 3 | NCT03158532 | Jul 2017 → Oct 2021 | — | Instituto de Cardiologia de Santa Catarina | Completed | No outcome recorded |
| Phase 3 | NCT02343276 | Feb → Aug 2015 | — | Instituto de Cardiologia de Santa Catarina | Completed | No outcome recorded |
| Phase 3 | NCT01864252 | Jan 2014 → Oct 2018 | myocardial disorder | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT01132391 | Jan → Apr 2009 | ulcer of anus and rectum | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT00493415 | Jun 2007 → Jul 2008 | infectious disease with sepsis | Frisius Medisch Centrum | Completed | No outcome recorded |
| Phase 3 | NCT00419419 | Dec 2006 → ? | Raynaud disease, scleroderma | MediQuest Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00266669 | Dec 2005 → May 2006 | Raynaud disease | MediQuest Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00121901 | Oct 2004 → Oct 2007 | pancreatitis | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00043719 | Jul 2002 → Dec 2007 | osteoporosis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 3 | NCT00000503 | Aug 1982 → Oct 1987 | coronary artery disorder, myocardial infarction, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT07391501 | Feb 2026 → Nov 2028 expected | internal hemorrhoid | Ying Zhu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07044232 | Oct 2025 → Sep 2026 expected | intracerebral hemorrhage | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07083063 | Sep 2025 → Jul 2027 expected | pancreatitis | National Cheng-Kung University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06682260 | Feb → Nov 2025 | heart failure | Copenhagen University Hospital, Hvidovre | Completed | No outcome recorded |
| Phase 4 | NCT05687669 | Jan → Apr 2023 | preeclampsia | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT06428669 | Aug 2022 → Aug 2025 | — | University of Virginia | Unknown | No outcome recorded |
| Phase 4 | NCT03809065 | Jan → May 2019 | hypotensive disorder | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03777605 | Dec 2018 → Dec 2020 | intermediate coronary syndrome | Kolding Sygehus | Unknown | No outcome recorded |
| Phase 4 | NCT03304496 | Mar 2018 → Mar 2019 | coronary artery disorder | Instituto Nacional de Cardiologia Ignacio Chavez | Suspended | No outcome recorded |
| Phase 4 | NCT03305848 | Aug 2017 → Apr 2019 | esophageal disorder | HealthPartners Institute | Completed | No outcome recorded |
| Phase 4 | NCT02708251 | Oct 2016 → May 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT02265965 | Oct 2015 → Jul 2018 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02085213 | Sep 2014 → Jul 2017 | placenta disorder | University of Edinburgh | Completed | No outcome recorded |
| Phase 4 | NCT01920074 | Jun 2013 → Mar 2015 | — | Forest Laboratories | Withdrawn | No outcome recorded |
| Phase 4 | NCT01685710 | Apr 2013 → May 2015 | kidney failure | University Hospital Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT00512759 | Dec 2007 → Aug 2018 | symptomatic heart failure | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT00479908 | Jan 2004 → Sep 2005 | intermediate coronary syndrome | University of Edinburgh | Completed | No outcome recorded |
| Phase not applicable25 trials | ||||||
| — | NCT07603037 | Jul 2026 → Jul 2027 expected | acute respiratory failure, aortic disorder, hypertensive disorder | First Affiliated Hospital of Wannan Medical College | Not yet recruiting | No outcome recorded |
| — | NCT07159334 | Aug → Dec 2025 overdue | hemorrhoid | King Edward Medical University | Recruiting | No outcome recorded |
| — | NCT06925763 | Apr 2025 overdue | disease of bone structure, periodontal disorder | Minia University | Not yet recruiting | No outcome recorded |
| — | NCT06637956 | Jan → Jun 2024 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT05855954 | May 2023 → Aug 2025 overdue | acute kidney injury | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT06238882 | Feb 2023 → Dec 2026 expected | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | National Cancer Institute of Mexico | Recruiting | No outcome recorded |
| — | NCT05443061 | Sep 2022 → Mar 2025 | ischemic disease | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT07214129 | Mar 2022 → Mar 2023 | pulmonary arterial hypertension | Mansoura University | Completed | No outcome recorded |
| — | NCT04686760 | Nov 2020 → Dec 2021 | COVID-19 | University of Lahore | Completed | No outcome recorded |
| — | NCT04564521 | Sep 2020 → Jun 2024 | retinoblastoma | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT03917004 | Apr → Sep 2019 | hypotensive disorder | Liang Bing | Unknown | No outcome recorded |
| — | NCT03849183 | Mar → Jul 2019 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT03481582 | Nov 2017 → Mar 2018 | female infertility, polycystic ovary syndrome | Ain Shams University | Completed | No outcome recorded |
| — | NCT02906553 | Sep 2016 → Apr 2019 | schizophrenia | King's College London | Completed | No outcome recorded |
| — | NCT02164318 | Sep 2014 → Feb 2016 | end stage renal failure | Duke University | Terminated | No outcome recorded |
| — | NCT02115724 | Apr 2014 → Dec 2026 expected | cardiovascular disorder | Augusta University | Active not recruiting | No outcome recorded |
| — | NCT02059018 | Feb 2014 → Feb 2015 | retinal ischemia | University of Aarhus | Completed | No outcome recorded |
| — | NCT01901419 | Jul 2013 → Jun 2017 | hyperglycemia, lactic acidosis | Tri-Service General Hospital (TSGH) | Completed | No outcome recorded |
| — | NCT01675700 | Jan → Jul 2009 | myofascial pain syndrome | GF Strong Rehabilitation Centre | Completed | No outcome recorded |
| — | NCT00838695 | Jan 2009 → Dec 2010 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00363571 | Aug 2006 → May 2007 | migraine disorder | Danish Headache Center | Unknown | No outcome recorded |
| — | NCT00375362 | Jul → Sep 2006 | — | Rabin Medical Center | Unknown | No outcome recorded |
| — | NCT00335010 | May → Dec 2005 | esophageal cancer | Erasmus Medical Center | Completed | No outcome recorded |
| — | NCT00257985 | Apr 2005 → Mar 2006 | familial hemiplegic migraine | Danish Headache Center | Completed | No outcome recorded |
| — | NCT00363792 | ? → May 2007 | — | Danish Headache Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 73 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03059316 Comparator | Jun 2016 → Apr 2017 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT04017845 Comparator | Apr 2015 → May 2017 | adenomatous colon polyp, colorectal cancer | Lewai Sharki Abdulaziz, MSc PhD | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT04594629 Comparator | Nov 2020 → May 2021 | pulmonary hypertension | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT00841594 Comparator | Feb 2009 | Raynaud disease | MediQuest Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00700518 Comparator | Jun → Nov 2008 | Raynaud disease | Procris Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00513994 Comparator | Aug → Oct 2007 | — | MediQuest Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04220281 Comparator | Dec 2019 → Feb 2020 | — | Ain Shams University | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03478332 Comparator | Jun 2017 → May 2020 | coronary artery disorder | Affiliated Hospital of Changchun University of Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06107465 Comparator | Nov 2023 → Jun 2024 | pulmonary edema | Alexandria University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03716050 Comparator | Jan 2018 → Mar 2019 | — | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT00953303 Comparator | Jan 2009 → Sep 2011 | heart failure | Hebei Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT00419549 Comparator | Oct 2003 → Sep 2005 | acute pancreatitis | All India Institute of Medical Sciences | Terminated | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT06912139 Comparator | Apr → Jun 2023 | coronary vasospasm | University of Medicine and Pharmacy "Victor Babes" Timisoara | Completed | No outcome recorded |
| Phase 3 | NCT06301880 Comparator | Jan 2022 → Jan 2023 | — | Damascus University | Completed | No outcome recorded |
| Phase 3 | NCT05837403 Background | Oct 2020 → Jul 2022 | ulcer of anus and rectum | Al-Kindy College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03689946 Background | Mar 2019 → Jan 2023 | cardiovascular disorder, hyperlipidemia | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03787030 Comparator | Dec 2018 → Feb 2019 | — | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT03813992 Comparator | Nov 2018 → Jul 2019 | erectile dysfunction | Futura Medical Developments Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03622060 Comparator | Jun 2018 → May 2019 | arterial occlusion, isoproterenol-mediated vasodilatation, radial neuropathy | Hermina Heart Center Kemayoran | Completed | No outcome recorded |
| Phase 3 | NCT02413268 Comparator | Mar 2016 → Jul 2020 | arterial occlusion | Total Cardiovascular Solutions | Unknown | No outcome recorded |
| Phase 3 | NCT02700438 Comparator | Jan 2014 → Jan 2016 | — | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT01387672 Comparator | Sep 2011 → Dec 2014 | osteoporosis | University of Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00934427 Comparator | Jun 2009 → Jun 2010 | Raynaud disease | MediQuest Therapeutics | Unknown | No outcome recorded |
| Phase 3 | NCT00803634 Comparator | Dec 2008 → Feb 2012 | heart failure, hypertensive disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 3 | NCT00577304 Comparator | Dec 2007 → Mar 2008 | Raynaud disease, scleroderma | MediQuest Therapeutics | Unknown | No outcome recorded |
| Phase 3 | NCT00252421 Comparator | Oct 2005 → Jun 2010 | osteoporosis | University of Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00093886 Comparator | Apr 2004 → Mar 2005 | hypertensive disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 3 | NCT00989716 Comparator | Jul 2001 → Oct 2013 | stroke disorder | University of Nottingham | Unknown | No outcome recorded |
| Phase 421 trials | ||||||
| Phase 4 | NCT06859554 Comparator | Mar → May 2025 | anal spasm | Hafiz Muhammad Hamza | Completed | No outcome recorded |
| Phase 4 | NCT05616455 Comparator | Oct 2021 → Mar 2022 | ulcer of anus and rectum | Treviso Regional Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04661709 Background | Mar 2021 → Mar 2023 | intermediate coronary syndrome | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04270279 Background | Dec 2020 → Aug 2021 | coronary artery disorder | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04270071 Background | Dec 2020 → Oct 2021 | coronary artery disorder | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04355598 Comparator | Apr → Aug 2020 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04002544 Comparator | Sep → Nov 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT04320498 Background | Jan → Dec 2019 | ulcer of anus and rectum | KTO Karatay University | Completed | No outcome recorded |
| Phase 4 | NCT03252665 Comparator | Sep 2017 → Jun 2019 | ST-elevation myocardial infarction | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03251599 Comparator | Aug → Nov 2017 | — | Recep Tayyip Erdogan University | Completed | No outcome recorded |
| Phase 4 | NCT02961946 Comparator | Mar → Oct 2017 | coronary artery disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01996436 Comparator | Aug 2016 → Apr 2024 | intracranial vasospasm | Peng Roc Chen, MD | Terminated | No outcome recorded |
| Phase 4 | NCT03296670 Comparator | Aug 2015 → Apr 2017 | ST-elevation myocardial infarction, coronary artery disorder | RenJi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02209636 Background | Sep 2014 → Jun 2019 | cardiovascular disorder, chronic kidney disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT02583633 Comparator | Oct 2013 → Oct 2014 | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01999517 Comparator | Jun 2013 → Jun 2018 | acute tubulointerstitial nephritis | Mt. Sinai Medical Center, Miami | Completed | No outcome recorded |
| Phase 4 | NCT02254252 Comparator | Mar 2012 → Mar 2013 | nonobstructive coronary artery disease | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01502943 Background | May → Dec 2011 | intermediate coronary syndrome | Liaoning University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00712894 Comparator | Dec 2006 → Apr 2009 | acute myocardial infarction | Fudan University | Completed | No outcome recorded |
| Phase 4 | NCT00431691 Comparator | Sep 2006 → Dec 2007 | escherichia coli infection, retinal disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00842023 Comparator | Jul 2006 → Jul 2008 | heart failure | Western University of Health Sciences | Completed | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT05741229 Comparator | Jan → Dec 2024 | pulmonary hypertension, neonatal, respiratory system disorder | Alexandria University | Completed | No outcome recorded |
| — | NCT05952011 Background | Aug 2023 → Feb 2025 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT05718310 Comparator | Nov 2022 → Dec 2024 | migraine disorder | IRCCS National Neurological Institute "C. Mondino" Foundation | Unknown | No outcome recorded |
| — | NCT05590520 Comparator | Nov 2022 → Nov 2023 | ulcer of anus and rectum | Pak Emirates Military Hospital | Unknown | No outcome recorded |
| — | NCT07585201 Comparator | Sep 2022 → Feb 2023 | hypotensive disorder | Zagazig University | Completed | No outcome recorded |
| — | NCT05682716 Background | Jul → Nov 2022 | acute kidney injury | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| — | NCT07074834 Background | Feb 2021 → Sep 2022 | coronary artery disorder | Shiyan City Renmin Hospital | Completed | No outcome recorded |
| — | NCT04918563 Comparator | Sep 2020 → Apr 2021 | mouth mucosa disorder | Semmelweis University | Completed | No outcome recorded |
| — | NCT03605095 Comparator | Jul → Aug 2018 | mouth disorder | Semmelweis University | Completed | No outcome recorded |
| — | NCT03528772 Comparator | May 2018 → Aug 2019 | — | Mansoura University | Completed | No outcome recorded |
| — | NCT03408054 Comparator | Jan → Apr 2018 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT03102502 Background | Mar 2017 → Oct 2018 | coronary artery disorder | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT02499484 Comparator | Sep 2016 → Nov 2018 | disease of the tendon | Royal College of Surgeons, Ireland | Completed | No outcome recorded |
| — | NCT04220606 Background | Apr 2015 → Apr 2016 | migraine without aura | Leiden University Medical Center | Completed | No outcome recorded |
| — | NCT02105493 Comparator | Oct 2013 → Feb 2014 | — | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | No outcome recorded |
| — | NCT02083055 Comparator | Dec 2012 → Feb 2014 | hypotensive disorder | Mahidol University | Completed | No outcome recorded |
| — | NCT01608880 Comparator | Aug 2012 → Mar 2014 | breast disorder | University of British Columbia | Completed | No outcome recorded |
| — | NCT01490073 Comparator | Mar → Nov 2012 | — | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT01212874 Comparator | Dec 2010 → Jun 2014 | hypertensive disorder | Loma Linda University | Completed | No outcome recorded |
| — | NCT01104597 Background | Apr 2010 → Dec 2012 | — | Northwell Health | Withdrawn | No outcome recorded |
| — | NCT00586261 Comparator | Mar 2006 → Jan 2009 | chronic kidney disease | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT00896311 Comparator | Mar 2003 → Oct 2006 | pregnancy disorder | University of Calgary | Completed | No outcome recorded |
| — | NCT00901758 Comparator | Mar 2003 → Oct 2006 | pregnancy disorder | University of Calgary | Completed | No outcome recorded |
| — | NCT00810381 Comparator | Jan → Jun 1999 | glaucoma | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 181 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nitroglycerin | “Those who tolerate all formulations will enter the 12-week treatment phase and be randomly assigned to one of five groups: 0.3 mg sublingual nitroglycerin tablet, 0.6 mg of the...” PMID 24010992 ↗ Sep 2013130“The ideal treatment would be a safe, inexpensive, quickly effective medication without significant side effects that could be administered without sedation or extensive...” NCT03305848 ↗ “milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline,...” NCT06301880 ↗ “A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of...” NCT00641953 ↗ “On the third day, under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.” NCT06172998 ↗ “using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).” NCT00512759 ↗ “Nitroglycerin (Nitrostat) is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.” NCT04008732 ↗ “Guideline- driven standard medical treatment including statins,antiplatelet drugs(aspirin or Clopidogrel ), anti-ischemic drugs (Nitroglycerin)” NCT03102502 ↗ “Application of nitroglycerin (glyceryl trinitrate) ointment with perianal administration is a widely used treatment for chronic anal fissure.” PMID 22810476 ↗ Aug 2012 “Nitroglycerin patches have been found to cause alleviation of pain especially when used in conjuction with morphine.” NCT00375362 ↗ “we maintain the patient's central venous pressure below 10 mmHg by adjusting the posture and pumping nitroglycerin.” NCT05855954 ↗ “Local nitroglycerin (NTG) was successfully used as a vasodilator to facilitate cannulation of the radial artery.” NCT04002544 ↗ “Topical Nitroglycerin Prior to Trans-radial Coronary Angiography: a Phase 2, Randomized Controlled Trial” NCT06289946 ↗ “treatment with either topical nitroglycerin or botulinum toxin is effective as an alternative to surgery” NCT05590520 ↗ “Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)” NCT00838695 ↗ “SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times.” NCT03259165 ↗ “Nitropaste is a topical agent that contains 2% nitroglycerin.” NCT06428669 ↗ “Furosemide; torsemide; nitroglycerin; dopamine; Dobutamine” NCT00953303 ↗ “oral nitroglycerin tablets (0.5 mg twice daily)” NCT07074834 ↗ “Nitroglycerin: sublingual necessary.” NCT01502943 ↗ “nitroglycerin” NCT00803634 ↗ |
| Known as | Anrecta | “The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)” NCT04320498 ↗ |
| Known as | Discotrine | “INTERVENTION: The active drug was transdermal GN (Discotrine/Minitran, 3M Pharma) 15 mg/24 hours; placebo (PL) was an identical-looking patch applied before ERCP.” PMID 19410035 ↗ May 2009 |
| Known as | Glycerly Trinitrate | “Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal” NCT01811693 ↗ |
| Known as | glyceryl nitrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00121901 ↗ |
| Known as | glyceryl trinitrate | “The central aim of this phase 2a study is to identify a regimen of paramedic initiated glyceryl trinitrate antihypertensive therapy in acute stroke patients that is safe, is...” NCT01811693 ↗35“Nitroglycerin, also known as glyceryl trinitrate (GTN), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure.” NCT06925763 ↗ “0.4% Nitroglycerin ointment is an intra-anal formulation of nitroglycerin (glyceryl trinitrate) indicated for the treatment of chronic anal fissure pain.” PMID 16526822 ↗ 2006 “The aim of this study was to compare the effect of transdermal nitroglycerin (glyceryl trinitrate, GTN) and oral nifedipine for managing preterm labor.” NCT02583633 ↗ “Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers.” NCT00257985 ↗ “The Effect of Glyceryl Trinitrate (GTN) and Diamox on Cerebral Haemodynamics Judged With the Help of 3-Tesla MRI.” NCT00363571 ↗ “Experimental and anecdotal evidence has supported the use of transdermal glyceryl trinitrate (GTN) patches.” PMID 27470183 ↗ Jul 2016 “Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.” NCT00121901 ↗ “self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day” NCT04320498 ↗ “glyceryl trinitrate, beta-Blocking agent,etc” NCT03478332 ↗ |
| Known as | GTN | “Eleven agents were used (nitroglycerin ointment (GTN), isosorbide dinitrate, Botulinum toxin (Botox), diltiazem, nifedipine (Calcium channel blockers or CCBs), hydrocortisone,...” PMID 17054170 ↗ Oct 200616“The role of intravenous glyceryl trinitrate (GTN) therapy administered during cardiac surgery as a cardioprotective agent and whether it interferes with RIC cardioprotection is...” PMID 26412308 ↗ Sep 2015 “Glyceryl trinitrates (GTN) is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure” NCT05687669 ↗ “Nitroglycerin, also known as glyceryl trinitrate (GTN), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure.” NCT06925763 ↗ “The aim of this study was to compare the effect of transdermal nitroglycerin (glyceryl trinitrate, GTN) and oral nifedipine for managing preterm labor.” NCT02583633 ↗ “Nitrates, such as glyceryl trinitrate (GTN), are drugs that release NO (NO donors) and are widely used in the treatment and prevention of angina.” NCT00479908 ↗ “Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers.” NCT00257985 ↗ “Although the large Efficacy of Nitric Oxide in Stroke (ENOS) trial of transdermal glyceryl trinitrate (GTN) was neutral” PMID 26463698 ↗ Oct 2015 “Participants will apply 0.2% Glyceryl Trinitrate (GTN) ointment to the anal region twice daily for four weeks.” NCT06859554 ↗ “Experimental and anecdotal evidence has supported the use of transdermal glyceryl trinitrate (GTN) patches.” PMID 27470183 ↗ Jul 2016 “Glyceryl trinitrate (GTN) is a well-established cardiovascular medicine that is also a nitric oxide donor” PMID 32436761 ↗ May 2020 “Sublingual glyceryl trinitrate (GTN) has been shown to produce periampullary sphincter relaxation.” PMID 11531863 ↗ Sep 2001 “analgesic effect of glyceryl trinitrate cream (GTN) in reducing pain during IUD insertion” PMID 30898632 ↗ Mar 2019 “The most used experimental headache model is the glyceryl trinitrate model (GTN).” NCT00363571 ↗ “0.2% glyceryl trinitrate (GTN) ointment” NCT07159334 ↗ “the NO donor Glyceryl trinitrate (GTN)” NCT00363792 ↗ “Drug: Glyceryl trinitrate (GTN)” NCT04220606 ↗ |
| Known as | GTO | “Glyceryl trinitrate ointment (GTO): Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were...” NCT03787030 ↗ |
| Known as | hydralizine | “hydralizine” NCT00803634 ↗ |
| Known as | IMX-150 | “A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of...” NCT00641953 ↗ |
| Known as | iNTG | “The use of inhaled nitroglycerin (iNTG) as an alternative pulmonary vasodilator.” PMID 38490779 ↗ Dec 2023 |
| Known as | MED2005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03813992 ↗ |
| Known as | Minitran | “INTERVENTION: The active drug was transdermal GN (Discotrine/Minitran, 3M Pharma) 15 mg/24 hours; placebo (PL) was an identical-looking patch applied before ERCP.” PMID 19410035 ↗ May 2009 |
| Known as | MQX-303 | “The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in...” NCT00253331 ↗ |
| Known as | MQX-503 | “The purpose of this clinical study is to determine, in a controlled fashion, the ability of a topical formulation of Nitroglycerin, MQX-503, to improve the patient's health...” NCT00577304 ↗5“A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon” NCT00934427 ↗ “Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon” NCT00419419 ↗ “Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon” NCT00266669 ↗ “Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon” NCT00253331 ↗ “a fast acting topical formulation of Nitroglycerin, MQX-503” NCT00480753 ↗ |
| Known as | MQX0503 | “The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and...” NCT00577304 ↗ |
| Known as | MXQ-503 | “nitroglycerin 0.9 % (MXQ-503)” NCT00841594 ↗ |
| Known as | Nitoglycerine-Glycerile Tinitrade | “topical 0.2% GTN cream (Nitoglycerine-Glycerile Tinitrade 0.2%, 30 gm; E.S.A.G Pharma Co., Cairo, Egypt).” NCT03528772 ↗ |
| Known as | nitro glycerine | “Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine )” NCT04594629 ↗2“Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy” NCT05741229 ↗ “Topical Formulation of Nitroglycerine, Vascana®” NCT02688270 ↗ |
| Known as | Nitroderm | “In the treatment group a nitroglycerin preparation (Nitroderm) was applied to the flap area.” PMID 21542401 ↗ Nov 2010 |
| Known as | Nitroglycerin tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04270279 ↗ |
| Known as | Nitrostat | “Nitroglycerin (Nitrostat) is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.” NCT04008732 ↗ |
| Known as | NNG | “The objective was to evaluate the effect of nebulized nitroglycerin (NNG) in neonates with persistent pulmonary hypertension (PPHN).” PMID 40888971 ↗ Sep 2025 |
| Known as | NTG | “RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US...” NCT01920074 ↗10“OBJECTIVE: To determine whether uninterrupted administration of transdermal nitroglycerin (NTG) to induce nitrate cross-tolerance decreased the frequency or severity of...” PMID 37273224 ↗ Aug 2023 “Nitroglycerin (NTG) ointment is a potent topical vasodilator that increases local blood flow by dilating arteries and veins without altering the ratio of pre- to post-capillary...” NCT01608880 ↗ “Local nitroglycerin (NTG) was successfully used as a vasodilator to facilitate cannulation of the radial artery.” NCT04002544 ↗ “whether use of nitroglycerin (NTG) during CD has a protective effect.” PMID 27405400 ↗ Aug 2016 “nitroglycerin ointment (NTG) at 15 mg/day” NCT00252421 ↗ “glyceryl trinitrate (NTG, a NO donor)” NCT00419549 ↗ “Drug: Nitroglycerin (NTG)” NCT06682260 ↗ “Drug: Nitroglycerin (NTG)” NCT03357731 ↗ “Nitroglycerin (NTG)” NCT07083063 ↗ “Nitroglycerin (NTG)” NCT06637956 ↗ |
| Known as | Perlinganit | “Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):” NCT00810381 ↗ |
| Known as | RECTIV | “RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US...” NCT01920074 ↗ |
| Known as | Recto-Relief Nitroglycerin Ointment | “application of local Nitroglycerin ointment 2% (Recto-Relief Nitroglycerin Ointment, 30 g) applied twice daily.” NCT05837403 ↗ |
| Known as | Rectogesic | “Glyceryl trinitrate ointment (GTO): Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were...” NCT03787030 ↗3“Glyceryl trinitrate ointment (GTO): Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were...” NCT02700438 ↗ “Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment” PMID 16526822 ↗ 2006 “Rectogesic® (glyceryl trinitrate 0.4% ointment)” NCT01132391 ↗ |
| Known as | Vascana | “Vascana (0.9% nitroglycerin cream)” NCT02688270 ↗ |
| Action | Restore | “Reversing nitric oxide deficiency by using nitroglycerin may prevent further bone loss.” NCT00043719 ↗ |
| Route | Other | “intracoronary infusion of nitroglycerin” NCT00000503 ↗ |